Trial Profile
A Phase I, unicentric, open and dose escalation clinical trial to evaluate the safety and the activity of the oncolytic adenovirus VCN-01 in patients with refractory retinoblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 24 Apr 2024
Price :
$35
*
At a glance
- Drugs VCN 01 (Primary)
- Indications Retinoblastoma
- Focus Adverse reactions
- 19 Apr 2024 Planned End Date changed from 30 Jun 2022 to 1 Jul 2024.
- 19 Apr 2024 Planned primary completion date changed from 30 Jun 2022 to 15 Jun 2024.
- 19 Apr 2024 Status changed from recruiting to active, no longer recruiting.